

1 **Title**

2 **Self-collected oral, nasal and saliva samples yield sensitivity comparable to**
3 **professional-collected oro-nasopharyngeal swabs in SARS-CoV-2 diagnosis**

4
5 **Authors:**

6 Maximilian Gertler¹, Eva Krause⁵, Welmoed van Loon¹, Niklas Krug¹, Franka
7 Kausch¹, Chiara Rohardt¹, Heike Rössig³, Janine Michel⁵, Andreas Nitsche⁵, Marcus
8 A. Mall⁶, Olga Nikolai^{1*}, Franziska Hommes¹, Susen Burock², Andreas K. Lindner¹,
9 Frank P. Mockenhaupt¹, Ulrich Pison⁴, and Joachim Seybold³

10

11 **Affiliations**

12 ¹ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
13 Humboldt-Universität zu Berlin, Institute of Tropical Medicine and International
14 Health, Berlin, Germany

15 ² Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
16 Humboldt-Universität zu Berlin, and Berlin Institute of Health; Charité Comprehensive
17 Cancer Center, Berlin, Germany

18 ³ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
19 Humboldt-Universität zu Berlin, and Berlin Institute of Health; Medical Directorate,
20 Berlin, Germany

21 ⁴ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
22 and Humboldt-Universität zu Berlin; Department of Anaesthesiology and Intensive
23 Care Medicine, Berlin, Germany

24 ⁵ Robert Koch Institute - Centre for Biological Threats and Special Pathogens,
25 Division Highly Pathogenic Viruses ZBS1, Berlin, Germany

26 ⁶ Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
27 Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric
28 Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany

29

30

31

32 **Correspondence:**

33 Maximilian Gertler, Institute of Tropical Medicine and International Health, Charité –
34 Universitätsmedizin Berlin, Germany, Augustenburger Platz 1, 13353 Berlin, Email:
35 Maximilian.gertler@charite.de

36

37

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 Summary/Abstract

39 Introduction:

40 Containment of the COVID-19 pandemic requires broad-scale testing. Laboratory
41 capacities for real-time-PCR were increased, and are complemented by Ag-tests.
42 However, sample-collection still requires qualified personnel and protective
43 equipment, may produce transmission to others during conduct and travel, and is
44 perceived uncomfortable. We tested sensitivity of three simplified self-sampling
45 techniques compared to professional-collected combined oro-nasopharyngeal
46 samples (cOP/NP).

47 **Methods:** From 62 symptomatic COVID-19 outpatients, we obtained simultaneously
48 three self- and one professional-collected sample after initial confirmation in a testing
49 centre: (i) combination swab (tongue, cheek, both nasal vestibula, MS, (ii) saliva
50 sponge combined with both nasal vestibula, SN, and (iii) gargled tap water, GW, (iv)
51 professionally-collected cOP/NP (standard). We compared the results of SARS-CoV-
52 2 PCR-assays detecting E-gene and ORF1ab for the different sample types and
53 performed bivariate statistical analysis to determine the variables reducing sensitivity
54 of the self-collecting procedures.

55 **Results:** SARS-CoV-2 RNA was detected in all 62 professionally-collected cOP/NP.
56 MS and SN samples showed a sensitivity of 95.2% (95%CI 86.5-99.0) and GW
57 samples of 88.7% (78.1-95.3). Compared to the median *ct*-values of cOP/NP
58 samples for *E-gene* (20.7) and *ORF1ab* (20.2) these were higher for MS (22.6 and
59 21.8), SN (23.3 and 22.3), and for GW (30.3 and 29.8).

60 For MS and SN samples but not for GW specimens, false negativity in bivariate
61 analysis was associated with non-German mother-tongue, number of sampling
62 errors, and with symptom duration. For symptom duration of ≤ 8 days, test sensitivity
63 for SN samples was 98.2% (95%CI 90.4-100.0) and for MS 96.4% (95%CI 87.7-99.6)
64 and drops after day 8 below 90%.

65 **Discussion:** The study is limited to sensitivity of self-collection in symptomatic
66 patients. Still, in this group, self-collected oral/nasal/saliva samples are reliable
67 alternatives to professional-collected cOP/NP samples, if symptom duration does not
68 exceed eight days and operational errors are minimized. Self-sampling could
69 contribute to up-scaling of safe and efficient testing.

70

71 **Introduction**

72 Containment of the current COVID-19 pandemic(Lu et al., 2020, Zhu et al., 2020)
73 requires broad-scale testing capacities(Zhu and Wong, 2020) for patients, potentially
74 contagious persons and groups at risk of infection. Laboratory capacities for real-time
75 reverse transcriptase polymerase chain reaction (rtRT-PCR) have been significantly
76 increased in many countries, and are complemented by novel rapid test devices
77 based on antigen detection(Rai et al., 2021). Still, professional-collected
78 (oro-)nasopharyngeal samples are considered the gold standard(Marty et al., 2020,
79 Pan et al., 2020). However, this approach remains challenging considering the needs
80 of qualified medical personnel and protective equipment as well as the risk of
81 potential virus transmission to health care workers or others at testing-sites(Zhu and
82 Wong, 2020). Moreover, (oro-)nasopharyngeal sampling is being perceived as
83 uncomfortable, and possibly deterring, by many patients. Simplified sampling
84 techniques may help overcoming these limitations. Reliable self-collecting
85 procedures could be home-based and thus, contribute to reduced virus transmission
86 due to more rapid diagnosis and reduced mobility of potentially contagious persons.
87 Self-collected samples from the oral cavity, e.g. saliva or from the nasal vestibule
88 (anterior nasal cavity) are therefore being investigated as non-invasive, more
89 comfortable and less resource-intensive alternatives and show variable
90 reliability(Fernandez-Gonzalez et al., 2021, Tu Yuan-Po et al., 2020, Tu Y.P. et al.,
91 2020).

92 We performed a prospective manufacturer-independent sensitivity study in
93 symptomatic SARS-CoV-2 positive outpatients to examine whether combinations of
94 simple self-collection technics may be reliable alternatives to professional-collected
95 pharyngeal sampling. We obtained four simultaneous samples for rtRT-PCR testing
96 from these patients: one professional-collected, oro-nasopharyngeal swab sample
97 and three self-collected specimens using different simplified sampling procedures

98 from more distal locations in the upper respiratory tract. Herein, we present the
99 sensitivities using self-collected samples as compared to the gold standard.

100

101 **Methods**

102 **Study design and Participant Enrolment**

103 We calculated 60 patients with confirmed SARS-CoV-2 infection as necessary to
104 compare the sensitivity of rtRT-PCR assays in self-collected versus professional-
105 collected samples assuming a true sensitivity of 98%.

106 Between 7th December 2020 and 11th January 2021, we prospectively enrolled 62
107 SARS-CoV-2 infected outpatients into the present study. On the day before
108 enrolment, all patients had attended the central testing site of Charité –
109 Universitätsmedizin Berlin (Maechler et al., 2020), with symptoms compatible with
110 COVID-19. Professional-collected, combined oro-nasopharyngeal swabs were
111 subjected to RT-PCR at the central Charité laboratory. Upon results communication
112 and counselling *via* telephone, study participation was offered to patients.

113 Symptomatic patients were eligible in case of a confirmed RT-PCR test result not
114 older than 24 hours before phone contact, and location of residence enabling a home
115 visit on the same day. The study was reviewed by the ethics committee at Charité-
116 Universitätsmedizin Berlin, Germany (EA2/192/20), and written informed consent
117 was obtained prior to study entry.

118 A medical study team visited the participants and interviewed them on perception of
119 the below procedures, their professional and linguistic background and competences,
120 as well as on prior experience with swabs. Medical professionals collected an oro-
121 nasopharyngeal swab as reference sample. Next, the team handed written
122 instructions and necessary materials for three self-collecting procedures. To assess
123 independent patient-self-collection, the collections were observed without any

124 additional verbal instructions or intervention, and performance and irregularities were
125 documented by the study team. The three procedures of self-collection included (i)
126 MS (multi-swab): a combination swab from the tongue, the inner cheek and both
127 nasal vestibules (insertion 2-3 cm, twisting 4x), (ii) SN (saliva-nasal): insalivating of
128 the swab for 10-15 sec. before swabbing both nasal vestibules (insertion 2-3 cm,
129 twisting 4x), and (iii) GW (gargle water): collection of 10 ml of gargled tap water into a
130 plastic container (Sarsted^R, L494-9). Swabs used were nylon-flocked applicators with
131 1 ml of Amies preservation medium (ESwab[®] Copan, Italy).

132

133 **Laboratory analyses**

134 For this study, we performed a quadruplex RT-PCR assay to simultaneously detect
135 the *E-gene* and *ORF1ab* of SARS-CoV-2, the *c-myc* gene representing human
136 nucleic acid, and *KoMa*, an artificial sequence that has no significant homology to
137 any sequence in GenBank. Total RNA was extracted with the QIAamp Viral RNA
138 Mini Kit (Qiagen, Hilden, Germany). PCR was performed using the AgPath-ID[™]
139 One-Step RT-PCR Reagents kit (Applied Biosystems, Foster City, CA USA) on a Bio-
140 Rad CFX96 device. Cycling conditions were: 45°C for 15 min, 95°C for 10 min
141 followed by 45 cycles of 95°C for 15 s and 60°C for 30 s. The *E-Gene* primer and
142 probe sequences were taken from Corman et al.(Corman et al., 2020). The SARS-
143 CoV-2 specific *ORF1ab* assay was designed based on the 72 sequences that were
144 available at the time from Michel et al.(Michel et al., 2020). *KoMa* and human cell *c-*
145 *myc* were detected to serve as quality and internal amplification (*KoMa*) control for
146 potential inhibitors of RT-PCR and the respective sampling technique(Kirchner et al.,
147 2010). The cycle threshold-value (ct-value), i.e. the PCR cycle at which the
148 fluorescence signal crosses the detection threshold, was determined for each target
149 sequence.

150 Probit analysis revealed the limit of detection for the quadruplex PCR under the
151 above described conditions as 28.7 genome copies for the *E-Gene* assay and 32.0
152 genome copies for the *ORF1ab* assay. Tests with signals that crossed the detection
153 threshold were considered positive. All samples were measured on the day of
154 collection by using 140 μ l aliquots for RNA extraction, respectively.

155

156 **Statistical analyses**

157 Descriptive statistics used proportions, means \pm standard deviation (SD), or medians
158 with interquartile ranges (IQR), as applicable. Categorical variables were compared by
159 two-tailed Fisher's exact test, numeric variables by a Mann Whitney U-test, and
160 paired numeric data by a Wilcoxon Signed Rank test. Sensitivity and 95% confidence
161 interval (CI) were calculated for each sampling method.

162 We assessed the linear dependence between *ct*-values of the professional collected
163 swabs and *ct*-values of the self-collecting sampling methods by target gene, using
164 Pearson correlation (*r*). A binominal regression model was used to determine the
165 variables reducing sensitivity of the self-collecting procedures (negative RT-PCR)
166 compared to the correspondent professional collected sample. All computations were
167 performed using "R" version 3.6.3 for all analyses. $P < 0.05$ was considered to reflect
168 statistical significance.

169

170

171 Results

172

173 Comparison of sensitivities and *ct*-values by sampling technique

174 All 62 participants provided three self-collected samples ($n = 186$) in addition to the
175 62 newly obtained professional-collected oro-nasopharyngeal specimens. Half of the
176 patients were female, and their median age was 31.5 (range, 17-66). The median
177 time between onset of symptoms and enrolment was four days (range, 2-15).

178 Symptoms and other clinical variables are presented in table 1.

179 All 62 professional-collected samples tested positive for both SARS-CoV-2 target
180 genes, the *E-gene* and the *ORF1ab*. In all samples, regardless of sampling
181 technique, *c-myc* was detected, indicating that all contained human cells. This was
182 done using the *c-myc* PCR assay in a singleplex reaction, as samples which are
183 positive in the *E-gene* and *ORF1ab* PCR assays do not always allow the
184 amplification of the *KoMa* and *c-myc* controls in the quadruplex reaction. No signs of
185 PCR inhibition were detected.

186 Detection sensitivities for *E-gene* and *ORF1ab* differed depending on the self-
187 collecting procedure. For *E-gene*, MS samples were positive in 93.5% (range: 84.3-
188 98.2), SN samples in 95.2% (86.5-99.0), and GW samples in 87.1% (76.1-94.3). For
189 *ORF1ab*, both MS and SN samples were positive in 91.9% (82.2-97.3), and GW
190 samples in, 88.7% (78.1-95.3). Defining a sample as SARS-CoV-2 positive if either
191 *E-gene* or *ORF1ab* was detected, MS and the SN samples showed a sensitivity of
192 95.2% (86.5-99.0) and GW samples of 88.7% (78.1-95.3).

193 Figure 1 presents *ct*-values of all samples tested positive for *E-gene* and for
194 *ORF1ab*. Median *ct*-values of the professional collected samples was 20.7 for *E-*
195 *gene* and 20.2 for *ORF1ab*. Median *ct*-values of the self-collected samples were

196 slightly but significantly ($p < 0.05$) higher for MS (22.6 and 21.8) and SN (23.3 and
197 22.3), and substantially so for GW (30.3 and 29.8).

198 For both target genes, *ct*-values of all sampling techniques were significantly
199 correlated with their respective *ct*-values for the cOP/NP ($p < 0.001$ for all
200 comparisons), with the strongest correlation for the *E-gene* in MS ($r = 0.77$) and SN
201 ($r = 0.73$) (Figure 2).

202

203 **Factors associated with false-negative results in patient-collected samples**

204 In three (4.8%) MS and SN samples as well as in seven (11.3%) GW specimens,
205 none of the two SARS-CoV-2 genes were detected. These false negative results
206 were associated with high *ct*-values, i.e. low viral loads, in the corresponding
207 professional-collected swab (Table 2). For MS and SN samples, but not for GW
208 specimens, false negativity was also associated with a non-German mother-tongue,
209 the number of sampling procedure mistakes, and as a trend, with symptom duration.

210 In a binomial logistic regression model fit on our data, for every day of symptom
211 duration, the odds for a positive test decreased by 40% (OR, 0.6; 95%CI, 0.4-0.9;
212 $P = 0.01$, for both MS and SN samples). Following the model, sensitivity (as compared
213 to oro-nasopharyngeal swabs) dropped below 90% for symptom duration longer than
214 eight days. In addition, when only assessing patients with a symptom duration of less
215 than 8 days in our study population, test sensitivity for SN samples was 98.2%
216 (95%CI, 90.4, 100.0), for MS 96.4% (95%CI, 87.7, 99.6).

217

218 **Discussion**

219 Our findings indicate that self-collected samples provide only slightly reduced
220 sensitivity in the detection of SARS-CoV-2 by RT-PCR as compared to professional-
221 collected oro-nasopharyngeal samples. This is particularly true for sample collection

222 using swabs (MS, SN), for sampling in the first week of symptom onset and when
223 operational errors are minimized using comprehensive instructions.

224 Acceptable sensitivity when using self-collected samples including gargling
225 techniques has previously been reported(Fernandez-Gonzalez et al., 2021, Lee et
226 al., 2021, Lindner et al., 2020, McCulloch et al., 2020, Miguereles et al., 2020, Tu
227 Yuan-Po et al., 2020, Tu Y.P. et al., 2020, Wehrhahn et al., 2020, Wyllie et al., 2020).

228 Public health agencies like the US Centers for Disease Control and Prevention, the
229 Infectious Diseases Society of America, and the German Robert Koch Institute
230 consider self-collecting techniques for symptomatic patients as potential alternatives
231 under certain circumstances, However, they emphasize the scarcity of available data
232 and the potential of erroneous conduct and results(Centers for Disease Control and
233 Prevention, 2021, Kojima et al., 2020, Robert Koch Institute, 2021).

234 The critical temporal roles of viral shedding and sample collection was recognized
235 early during the pandemic(Woelfel et al., 2020, Zou et al., 2020). Our data confirm a
236 decrease of sensitivity when upper-respiratory tract samples are collected during the
237 second week of disease(Wyllie et al., 2020). The present data suggest that until day
238 eight of symptom onset, self-collected samples may be similarly reliable as
239 professional collected oro-nasopharyngeal samples with sensitivities of >98% (MS,
240 SN), and with some reservation also for GW (sensitivity >90%).

241 The gargling procedure performed below expectations. It is likely that the 10 ml water
242 used for gargling instead of 1 ml of transport medium for all other samples diluted
243 viral material in the GW sample. However, it is recommended by others(Goldfarb et
244 al., 2021, Kojima et al., 2020) and officially used in Austria.

245 Diagnostic tools in the hands of untrained people require education and
246 comprehensive instructions. Indeed, the false negative results of the patient-collected
247 procedures were associated with procedural errors and reduced German language
248 competence (written instructions in German). This shows an even higher potential for

249 sample self-collection when pictorial illustrations are offered, and in different
250 languages.

251 Supervision and support of self-collection procedures may be provided directly by
252 personnel through a window or *via* video consultation. Such would not require
253 personal protective equipment and still reduce transmission risks at testing sites.

254 With respect to the slightly reduced sensitivity of self-collected samples (MS and SN)
255 in this study, it needs to be taken into account that oro-nasopharyngeal swabbing
256 was performed by very experienced medical professionals. In a scenario of massive
257 up-scale of testing by public health systems this may not be the case, potentially
258 shrinking the sensitivity differences between professional and self-collection of
259 samples. This has particular significance for a central component of pandemic
260 response globally, i.e., repetitive testing of groups, e.g., school attendees or
261 employees as claimed also by the WHO(World Health Organization, 2021). For that,
262 testing including sample-collection needs to be simplified, non-invasive to prevent
263 refusal, efficient and safe. In this regard, we provide further evidence that (home)
264 sample self-collection may help to reduce test restraints, transmission risks as well
265 as human and material resources. This data refers only to self-collecting for RT-PCR
266 and not to self-collecting for rapid-tests. However the results may support the
267 reliability of self-testing based on rapid tests as public-health tool which is currently
268 becoming the most frequent test-method in the reality.

269 A limitation of our study is that only symptomatic patients were included. While there
270 is no reason to believe that self-collection does not work in asymptomatic individuals,
271 findings with respect to, e.g., symptom duration are not transferrable. Our study
272 among SARS-CoV-2 positive patients could not produce specificity data. However,
273 since specificity is predominantly determined by the diagnostic assay applied, we
274 assume that this parameter is comparable for the sampling method. Moreover,

275 potentially decreased specificity could still be addressed by confirming positivity *via*
276 professional sample collections.

277 **Conclusion:** Self-collected samples based on oral and nasal swabs for the detection
278 of SARS-CoV-2 by RT-PCR offer very similar sensitivity compared to professional-
279 collected oronasopharyngeal samples, if symptom duration does not exceed eight
280 days and operational errors are minimized using comprehensive instructions. Self-
281 sampling could thus optimize and complement containment and mitigation strategies
282 during pandemic conditions, save human and material resources, and reduce
283 transmission risks during sample collection and attending test sites.

284

285

286

287

288
289
290
291

Table 1: Patient characteristics and symptoms

	All patients (N=62) % (n) or median (range)
Female	50% (31)
Age (years)	31.5 (17.0, 66.0)
Shortness of breath	6.5% (4)
Chest pain/Chest tightness	0% (0)
Fever in the last 48 hours	30.6% (19)
Chills	38.7% (24)
Fatigue	80.6% (50)
Body aches	66.1% (41)
Cough	62.9% (39)
Rhinorrhea	67.7% (42)
Diarrhea	21% (13)
Sore throat	41.9% (26)
Headache	75.8% (47)
Impaired smell and taste	50% (31)
Time between test and symptom onset (days)	4.0 (2.0, 15.0)
Chronic lung disease	9.7% (6)
Diabetes I/II	1.6% (1)
Cardiovascular disease	8.1% (5)
Obesity	6.4% (4)
Contact to a confirmed SARS-CoV-2 case	33.9% (21)
Time between test and last contact (days)	6.0 (1.0, 10.0)
German NOT as first language	30.6% (19)

292
293
294


295

296 **Figure 1**

297 **Ct values for *E-gene* and the *ORF1ab* of all positive samples by type of sample**
298 **collection: professional-collected cOP/NP sample (white), patient-collected samples MS**
299 **(blue), SN (green), and GW (orange)**

300

301



302

303 **The boxes in the plot depict the 25th, 50th and 75th percentiles.**

304

305

306

307

308

309 **Table 2: Comparison of variables between negative and positive test result in patient**
 310 **collected samples separated by collection method**

311

Sample type	Variable	Negative	Positive	p-value
MS	N	3	59	
	Ct value of professionally collected cOP/NP, median (IQR)	27.2 (27.1, 30.4)	20.4 (17.2, 22.9)	0.008
	Female	1 (33.3%)	30 (50.8%)	1.000
	Age in years, median (range)	48.0 (35.0, 53.0)	31.0 (17.0, 66.0)	0.064
	Number of symptoms, median (range)	7.0 (7.0, 7.0)	5.0 (2.0, 10.0)	0.335
	Symptom interval in days, median (range)	11.0 (4.0, 15.0)	4.0 (2.0, 12.0)	0.083
	German is not first language	3 (100.0%)	16 (27.1%)	0.026
	No. of mistakes during sampling procedure, median (range)	2.0 (2.0, 3.0)	0.0 (0.0, 3.0)	0.005
SN	N	3	59	
	Ct value of professionally collected cOP/NP, median (IQR)	29.1 (28.1, 31.4)	20.4 (17.2, 22.9)	0.006
	Female	1 (33.3%)	30 (50.8%)	1.000
	Age in years, median (range)	35.0 (19.0, 48.0)	31.0 (17.0, 66.0)	0.948
	Number of symptoms, median (range)	3.0 (3.0, 3.0)	5.0 (2.0, 10.0)	0.127
	Symptom interval in days, median (range)	12.0 (4.0, 15.0)	4.0 (2.0, 11.0)	0.077
	German is not first language	3 (100.0%)	16 (27.1%)	0.026
	No. of mistakes during sampling procedure, median (range)	2.0 (1.0, 3.0)	0.0 (0.0, 3.0)	0.012
GW	N	7	55	
	Ct value of professionally collected OP/NP, median (IQR)	26.6 (23.4, 28.1)	20.1(17.1, 22.3)	< 0.001
	Female	4 (57.1%)	27 (49.1%)	1.000
	Age in years, median (range)	34.0 (19.0, 48.0)	31.0 (17.0, 66.0)	0.798
	Number of symptoms, median (range)	6.0 (3.0, 9.0)	5.0 (2.0, 10.0)	0.794
	Symptom interval in days, median (range)	4.0 (3.0, 15.0)	5.0 (2.0, 11.0)	0.804
	German is not first language	4 (57.1%)	15(27.3%)	0.187
	No. of mistakes during sampling procedure, median (range)	0.0 (0.0, 2.0)	0.0 (0.0, 2.0)	0.426


312 **MS – Multis-swab (cheek, tongue, nares), SN – Saliva-nasal (saliva, nasal vestibule), GW –**
 313 **gargle water. A patient sample was considered positive when either the e-gene or the ORF1ab-**
 314 **gene or both were detected.**
 315

316 **Figure 2**

317

318 **Ct-values of each patient-collected sample type (MS, SN, GW) compared with the ct-**
319 **value of the diagnostic standard (medical professional-collected OP/NP sample, x-axis)**
320 **shown for the used two target genes.**

321



322

323 **MS (Multi-swab – blue), SN (Saliva-nasal – green), GW (gargle water – orange)**

324

325

326 **Acknowledgements:** Mia Wintel, Julia Macos

327 **Author contributions to be completed:** MG, AKL, UP, FPM, FH, designed the
328 study and developed standard operating procedures. MG, UP, SB, NK, CH, FK, ON
329 implemented the study design, enrolled patients. MG led the writing of the
330 manuscript. EK, JM, AN were responsible for PCR testing and contributed to the
331 interpretation of the data. FPM, MG, HR and JS coordinated and supervised the
332 outpatient-testing center. CR, SB, FK, UP, NK and MG enrolled patients. WvL led the
333 data analysis. All authors have reviewed the manuscript.

334 **Data availability:** All raw data and analysis code are available upon a request to the
335 corresponding author.

336 **Conflict of interest:** None declared.

337 **Support statement:** The study was supported by Charité Universitaetsmedizin and
338 the Senate of Berlin

339

340

341

342 **References**

343 Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical
344 Specimens for COVID-19 Testing; 2021. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#handling-specimens-safely)
345 [nCoV/lab/guidelines-clinical-specimens.html#handling-specimens-safely](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#handling-specimens-safely). [Accessed March 31, 2021].

346 Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
347 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020;25(3).

348 Fernandez-Gonzalez M, Agullo V, de la Rica A, Infante A, Carvajal M, Garcia JA, et al. Performance of
349 saliva specimens for the molecular detection of SARS-CoV-2 in the community setting: does sample
350 collection method matter? *Journal of clinical microbiology* 2021.

351 Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, et al. Self-collected Saline Gargle
352 Samples as an Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for COVID-19
353 Diagnosis in Outpatients. *Journal of clinical microbiology* 2021.

354 Kirchner S, Kraemer KM, Schulze M, Pauly D, Jacob D, Gessler F, et al. Pentaplexed Quantitative Real-
355 Time PCR Assay for the Simultaneous Detection and Quantification of Botulinum Neurotoxin-
356 Producing Clostridia in Food and Clinical Samples. *Applied and Environmental Microbiology*
357 2010;76(13):4387-95.

358 Kojima N, Turner F, Slepnev V, Bacelar A, Deming L, Kodeboyina S, et al. Self-Collected Oral Fluid and
359 Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal
360 Swab Specimens for the Detection of SARS-CoV-2. *Clinical infectious diseases : an official publication*
361 *of the Infectious Diseases Society of America* 2020.

362 Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva, Oropharyngeal
363 Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic Review and Meta-
364 analysis. *Journal of clinical microbiology* 2021.

365 Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head comparison of
366 SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-
367 collected nasopharyngeal swab. *The European respiratory journal* 2020.

368 Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019
369 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565-
370 74.

371 Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, et al. Epidemiological and clinical
372 characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020-a
373 cross-sectional study. *Clin Microbiol Infect* 2020;26(12):1685.e7-.e12.

374 Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal Swab Specimen. *New England Journal*
375 *of Medicine* 2020;382(22).

376 McCulloch DJ, Kim AE, Wilcox NC, Logue JK, Greninger AL, Englund JA, et al. Comparison of
377 Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs
378 for Detection of SARS-CoV-2 Infection. *Jama Network Open* 2020;3(7).

379 Michel D, Danzer KM, Gross R, Conzelmann C, Muller JA, Freischmidt A, et al. Rapid, convenient and
380 efficient kit-independent detection of SARS-CoV-2 RNA. *J Virol Methods* 2020;286.

381 Miguères M, Mengelle C, Dimeglio C, Didier A, Alvarez M, Delotel P, et al. Saliva sampling for
382 diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. *Journal of*
383 *Clinical Virology* 2020;130.

- 384 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect*
385 *Dis* 2020;20(4):411-2.
- 386 Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent
387 developments in the diagnosis of COVID-19 infection. *Applied Microbiology and Biotechnology*
388 2021;105(2):441-55.
- 389 Robert Koch Institute. Hinweise zur Testung von Patienten auf Infektion mit dem neuartigen
390 Coronavirus SARS-CoV-2; 2021. Available from:
391 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Vorl_Testung_nCoV.html;jsessionid=CD421678C21E595557DF2DB07E1E590A.internet072?nn=13490888#doc13490982bodyText1.
392
393 [Accessed March 31, 2021 2021].
- 394 Tu Y-P, Jennings R, Berke EM. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2
395 Testing. *New England Journal of Medicine* 2020;383(5):494-6.
- 396 Tu YP, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, et al. Patient-collected tongue, nasal,
397 and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected
398 nasopharyngeal swabs. 2020.
- 399 Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, et al. Self-collection: An appropriate
400 alternative during the SARS-CoV-2 pandemic. *Journal of clinical virology : the official publication of*
401 *the Pan American Society for Clinical Virology* 2020;128:104417-.
- 402 Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Virological
403 assessment of hospitalized patients with COVID-2019. *Nature* 2020;581(7809):465-+.
- 404 World Health Organization. COVID-19 strategic preparedness and response plan: 1 February 2021 to
405 31 January 2022. Geneva: World Health Organization; 2021.
- 406 Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva
407 or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *New England Journal of Medicine*
408 2020;383(13):1283-6.
- 409 Zhu N, Wong PK. Advances in Viral Diagnostic Technologies for Combating COVID-19 and Future
410 Pandemics. *Slas Technology* 2020;25(6):513-21.
- 411 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
412 Pneumonia in China, 2019. *New England Journal of Medicine* 2020;382(8):727-33.
- 413 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory
414 Specimens of Infected Patients. *New England Journal of Medicine* 2020;382(12):1177-9.
415